Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors.
1. 系统已在2026-01-01 13:48:03对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/JCO.2025.43.16_suppl.8598
文献链接: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8598
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Guzman Alonso; Pilar Garrido; Judy S. Wang; Andrew G. Gianoukakis; Matthew H. Taylor; Stephen V. Liu; Luis G. Paz-Ares; Martin David Forster; David R. Spigel; Saad A. Khan; Jyoti D. Patel; Salman Rafi Punekar; Daniel Morgensztern; Susanne M. Arnold; Javier García-Corbacho; Matthew G. Krebs; Jack J. Welch; Sonia Serrano; Hendrik-Tobias Arkenau; Elena Garralda
